Ketalux - Ketamine Therapy EducationKetalux - Independent Ketamine Education
Comparison

Ketamine infusions vs Spravato

Both target the glutamate system for treatment-resistant depression, but they differ in molecule, route, FDA status, insurance coverage, and clinical evidence base. This guide compares them across the decisions patients actually face.

Written by: Ira ZootMedical review status: Not yet clinically reviewed.Last updated: July 19, 2026Evidence: Educational synthesis - not medical advice

This page has been written and edited by the publisher. It has not been reviewed by a licensed clinician.

Quick answer
Bottom line
Spravato offers FDA approval and insurance coverage in exchange for a strict schedule; racemic infusions offer flexibility and broader evidence in exchange for out-of-pocket cost. For most eligible patients the decision comes down to insurance coverage and clinic access rather than clinical superiority.

This page compares Ketamine infusions (IV/IM) and Spravato (esketamine nasal spray) across the same fixed dimensions - mechanism, evidence, onset, duration, side effects, access, suitability, and limits. It does not name a winner and does not recommend either option for you.

Related on Ketalux
Ketamine infusions (IV/IM)
Spravato (esketamine nasal spray)
Mechanism
Racemic ketamine (R + S enantiomers) delivered intravenously or intramuscularly; broader receptor activity beyond NMDA, including opioid and monoaminergic effects.
S-enantiomer only (esketamine); higher NMDA-receptor affinity, delivered as an intranasal spray absorbed through nasal mucosa.
Evidence
Large off-label evidence base including meta-analyses in TRD, bipolar depression, suicidal ideation, and PTSD; not FDA-approved for psychiatric use.
FDA-approved (2019) for TRD and (2020) for depressive symptoms with acute suicidal ideation, based on pivotal Phase III trials with adjunct oral antidepressant.
Onset
Antidepressant effect often within hours after the first infusion; peaks over an induction series of 6 sessions.
Response typically within 24 hours to 1 week; induction is twice-weekly for 4 weeks per FDA label.
Duration
Days to several weeks per session; maintenance highly variable by protocol.
Structured maintenance: weekly for weeks 5–8, then every 1–2 weeks per FDA label and REMS program.
Side effects
Dissociation, transient blood-pressure elevation, nausea, dizziness; bladder toxicity is a concern only at recreational-use frequencies.
Dissociation, sedation, dizziness, nausea, blood-pressure elevation; mandatory 2-hour in-clinic monitoring after every dose per REMS.
Access
Off-label at specialty clinics; paid out of pocket in most cases and rarely covered by insurance; per-session cost and protocol vary widely between clinics.
REMS-certified centers only; commonly covered by commercial insurance and Medicare with prior authorization; standardized dosing.
Best for
Patients who want protocol flexibility, do not meet TRD criteria required by Spravato, cannot access a REMS site, or have not tolerated intranasal delivery.
Patients meeting FDA TRD criteria (failure of ≥2 antidepressants), with insurance coverage, and who can commit to the twice-weekly in-clinic schedule.
Limits
Cost paid out of pocket, variable clinic quality, no standardized maintenance protocol, off-label regulatory status.
Rigid FDA-mandated schedule, 2-hour monitoring window, prior-authorization delays, must remain on an oral antidepressant per label.
Disclaimer
This comparison is educational and general. It is not a recommendation. Treatment choice depends on your individual history, diagnosis, prior response, preferences, and access - discuss with a qualified clinician.
About the author

Publisher and editor of Ketalux, based in Chicago, Illinois. Ira is a ketamine therapy patient, not a clinician. This is editorial review, not medical review: Ira is not a licensed clinician and does not provide diagnosis or medical care. Ketalux does not accept compensation from providers in exchange for favorable editorial coverage, evidence ratings, recommendations, patient referrals, or organic provider ranking. Read the full publisher disclosure →

Educational use only. The content on this page is provided for general educational purposes and does not constitute medical advice, diagnosis, or treatment. Ketamine and related therapies carry risks and are appropriate only under qualified medical supervision. Always consult a licensed healthcare professional about your individual situation. Information may change as research evolves.